Amgen drug misses endpoint in acute heart failure trial PMLiVE A drug in development by Amgen and Cytokinetics to treat symptoms of heart failure has missed its primary endpoint in a phase II trial. During the ATOMIC-AHF trial involving 613 patients with left ventricular systolic dysfunction hospitalised for acute ... |
